Patents by Inventor Sarel Fleishman

Sarel Fleishman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10688330
    Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 23, 2020
    Assignees: Yeda Research and Development Co. Ltd., University of Washington
    Inventors: Dan S. Tawfik, Haim Leader, Yaacov Ashani, Izhack Cherny, Moshe Goldsmith, Per Jr. Greisen, Sagar D. Khare, Gustav Oberdorfer, David Baker, Sarel Fleishman, Adi Goldenzweig, Nidhi Aggarwal
  • Patent number: 10665324
    Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: May 26, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Sarel Fleishman, Gideon Lapidoth, Maria Gabriele Pszolla, Christoffer Norn
  • Publication number: 20200058367
    Abstract: A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 20, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Sarel FLEISHMAN, Adi GOLDENZWEIG, Dan S. TAWFIK
  • Publication number: 20190374629
    Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising Reticulocyte-binding protein Homologue 5 (PfRH5) antigens. In particular, the invention provides modified PfRH5 antigens rationally designed to produce improved stability and expression profiles whilst maintaining immunogenicity.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 12, 2019
    Inventors: Simon J. Draper, Ivan Campeotto, Matthew K. Higgins, Sarel Fleishman, Adi Goldenzweig
  • Patent number: 10468119
    Abstract: A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 5, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Sarel Fleishman, Adi Goldenzweig, Dan S. Tawfik
  • Publication number: 20190083836
    Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 21, 2019
    Inventors: Dan S. TAWFIK, Haim LEADER, Yaacov ASHANI, Izhack CHERNY, Moshe GOLDSMITH, Per Jr. GRIESEN, Sagar D KHARE, Gustav Oberdorfer, David Baker, Sarel Fleishman, Adi Goldenzweig, Nidhi Aggarwal
  • Publication number: 20170206308
    Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.
    Type: Application
    Filed: July 6, 2015
    Publication date: July 20, 2017
    Inventors: Sarel FLEISHMAN, Gideon LAPIDOTH, Maria Gabriele PSZOLLA, Christoffer NORN
  • Publication number: 20170032079
    Abstract: A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.
    Type: Application
    Filed: September 8, 2016
    Publication date: February 2, 2017
    Inventors: Sarel FLEISHMAN, Adi Goldenzweig, Dan S. Tawfik
  • Patent number: 9388217
    Abstract: Polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection are disclosed. Isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention are disclosed. Antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier are disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 12, 2016
    Assignee: University of Washington through its Center for Commercialization
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Publication number: 20160024155
    Abstract: Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection.
    Type: Application
    Filed: October 7, 2015
    Publication date: January 28, 2016
    Inventors: David BAKER, Timothy A. WHITEHEAD, Sarel FLEISHMAN
  • Patent number: 9181300
    Abstract: Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: November 10, 2015
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Publication number: 20150038408
    Abstract: The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 5, 2015
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Publication number: 20140206628
    Abstract: Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: University of Washington through its Center for Commercialization
    Inventors: David BAKER, Timothy A. WHITEHEAD, Sarel FLEISHMAN
  • Patent number: 8765686
    Abstract: Isolated polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection, or to diagnose or monitor progression of an influenza infection are described.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 1, 2014
    Assignee: University of Washington through its Center for Commercialization
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
  • Publication number: 20130143794
    Abstract: The present invention provides polypeptides according to the general formulas disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 3, 2011
    Publication date: June 6, 2013
    Applicant: University of Washington through its Center for Commercialization
    Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman